Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cullin-4-RING E3 ubiquitin ligase (CRL4) is a multi-subunit protein complex that plays a pivotal role in the ubiquitin-proteasome system by targeting specific substrates for degradation. The core complex is composed of a Cullin-4 scaffold (either CUL4A or CUL4B), the RING-finger protein RBX1 (also known as ROC1), and the adaptor protein DDB1, which recruits a variety of DDB1- and CUL4-associated factors (DCAFs) to act as substrate receptors. CRL4 regulates critical cellular processes, including DNA replication licensing (by degrading CDT1), nucleotide excision repair, cell cycle progression, and chromatin remodeling. Dysregulation or overexpression of CUL4 is implicated in various malignancies, such as lung, breast, and ovarian cancers, where it promotes tumor progression and metastasis, while mutations in CUL4B are linked to X-linked intellectual disability. CRL4 has emerged as a highly attractive therapeutic target, particularly through the use of molecular glues like immunomodulatory drugs (IMiDs; e.g., thalidomide, lenalidomide) and sulfonamides (e.g., indisulam), which hijack CRL4 substrate receptors (CRBN and DCAF15, respectively) to induce the degradation of neo-substrates. Additionally, direct small-molecule inhibitors of the CRL4 catalytic core (such as KH-4-43 and PA-1) are under development to block its activity and induce apoptosis in cancer cells.
E3 ubiquitin ligase modulation, targeted protein degradation, E3 ubiquitin ligase inhibition, and molecular glue recruitment
11 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cullin-4-RING E3 ubiquitin ligase (CRL4).